A. Schoberth

583 total citations
15 papers, 476 citations indexed

About

A. Schoberth is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Immunology. According to data from OpenAlex, A. Schoberth has authored 15 papers receiving a total of 476 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Radiology, Nuclear Medicine and Imaging, 7 papers in Oncology and 5 papers in Immunology. Recurrent topics in A. Schoberth's work include Monoclonal and Polyclonal Antibodies Research (7 papers), Immunotherapy and Immune Responses (4 papers) and HER2/EGFR in Cancer Research (3 papers). A. Schoberth is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), Immunotherapy and Immune Responses (4 papers) and HER2/EGFR in Cancer Research (3 papers). A. Schoberth collaborates with scholars based in Germany, Hungary and Switzerland. A. Schoberth's co-authors include Horst Lindhofer, Peter Ruf, Michael Jäger, M. M. Heiss, Michael A. Ströhlein, Jürgen Hess, Christian Schindlbeck, Brigitte Rack, Thomas Zwingers and Julia Jückstöck and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and International Journal of Cancer.

In The Last Decade

A. Schoberth

15 papers receiving 462 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Schoberth Germany 10 355 209 128 102 78 15 476
L. Dirix Belgium 9 357 1.0× 93 0.4× 70 0.5× 120 1.2× 86 1.1× 15 483
Véronique Cabaret France 9 392 1.1× 229 1.1× 149 1.2× 158 1.5× 90 1.2× 20 588
Suad Bin Amer Saudi Arabia 7 503 1.4× 80 0.4× 280 2.2× 124 1.2× 98 1.3× 8 666
Elena Bonazzoli United States 15 319 0.9× 122 0.6× 76 0.6× 147 1.4× 99 1.3× 31 531
E Holz Germany 5 284 0.8× 194 0.9× 184 1.4× 143 1.4× 55 0.7× 8 475
Denise Darrah United States 10 240 0.7× 102 0.5× 143 1.1× 82 0.8× 53 0.7× 16 423
P. Hirnle Germany 11 250 0.7× 108 0.5× 18 0.1× 91 0.9× 110 1.4× 31 454
Kimberley M. Heinhuis Netherlands 10 508 1.4× 47 0.2× 261 2.0× 202 2.0× 197 2.5× 15 797
Chimera R. Peet United States 5 268 0.8× 108 0.5× 38 0.3× 211 2.1× 127 1.6× 5 510
Winifred Lo United States 8 289 0.8× 49 0.2× 181 1.4× 138 1.4× 40 0.5× 15 455

Countries citing papers authored by A. Schoberth

Since Specialization
Citations

This map shows the geographic impact of A. Schoberth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Schoberth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Schoberth more than expected).

Fields of papers citing papers by A. Schoberth

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Schoberth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Schoberth. The network helps show where A. Schoberth may publish in the future.

Co-authorship network of co-authors of A. Schoberth

This figure shows the co-authorship network connecting the top 25 collaborators of A. Schoberth. A scholar is included among the top collaborators of A. Schoberth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Schoberth. A. Schoberth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Pietzner, Klaus, Michael Jäger, A. Schoberth, et al.. (2011). First patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report. Medical Oncology. 29(2). 1391–1396. 11 indexed citations
3.
Rack, Brigitte, Julia Jückstöck, Ulrich Andergassen, et al.. (2011). Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. Archives of Gynecology and Obstetrics. 285(2). 485–492. 39 indexed citations
4.
Jäger, Michael, A. Schoberth, Peter Ruf, et al.. (2011). Immunomonitoring Results of a Phase II/III Study of Malignant Ascites Patients Treated with the Trifunctional Antibody Catumaxomab (Anti-EpCAM × Anti-CD3). Cancer Research. 72(1). 24–32. 88 indexed citations
5.
Jäger, Markus, A. Schoberth, Martin Hennig, et al.. (2010). The trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3) in patients with malignant ascites: Immunomonitoring results of a pivotal phase II/III study (pooled population).. Journal of Clinical Oncology. 28(15_suppl). 2521–2521. 1 indexed citations
6.
Rack, Brigitte, Julia Jückstöck, A. Schoberth, et al.. (2010). Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer.. PubMed. 30(5). 1807–13. 99 indexed citations
7.
Jäger, Michael, et al.. (2009). Decrease of VEGF within malignant ascites during catumaxomab treatment: Results from a pivotal phase II/III study. Journal of Clinical Oncology. 27(15_suppl). 3029–3029. 3 indexed citations
8.
Jäger, Michael, A. Schoberth, Peter Ruf, Jürgen Hess, & Horst Lindhofer. (2009). The Trifunctional Antibody Ertumaxomab Destroys Tumor Cells That Express Low Levels of Human Epidermal Growth Factor Receptor 2. Cancer Research. 69(10). 4270–4276. 79 indexed citations
9.
Lindhofer, Horst, et al.. (2009). Elimination of cancer stem cells (CD133+/EpCAM+) from malignant ascites by the trifunctional antibody catumaxomab: Results from a pivotal phase II/III study. Journal of Clinical Oncology. 27(15_suppl). 3014–3014. 10 indexed citations
10.
JAGER, MJ, et al.. (2008). Effect on low HER2 (1+) expressing tumor cells of the trifunctional antibody ertumaxomab. Journal of Clinical Oncology. 26(15_suppl). 3071–3071. 4 indexed citations
11.
Weckermann, Dorothea, Alfred Zippelius, A. Schoberth, et al.. (2007). A multimarker real-time RT-PCR for MAGE-A gene expression allows sensitive detection and quantification of the minimal systemic tumor load in patients with localized cancer. Journal of Immunological Methods. 323(2). 180–193. 12 indexed citations
12.
Heiss, M. M., Michael A. Ströhlein, Michael Jäger, et al.. (2005). Immunotherapy of malignant ascites with trifunctional antibodies. International Journal of Cancer. 117(3). 435–443. 91 indexed citations
13.
Rack, Brigitte, W Janni, A. Schoberth, et al.. (2004). Effect of zoledronate on persisting isolated tumor cells (ITC) in the bone marrow (BM) of patients without recurrence of early breast cancer. Journal of Clinical Oncology. 22(14_suppl). 9515–9515. 13 indexed citations
14.
15.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. Dirix Breakdown of academic impact, for papers by Véronique Cabaret Breakdown of academic impact, for papers by Suad Bin Amer Breakdown of academic impact, for papers by Elena Bonazzoli Breakdown of academic impact, for papers by E Holz Breakdown of academic impact, for papers by Denise Darrah Breakdown of academic impact, for papers by P. Hirnle Breakdown of academic impact, for papers by Kimberley M. Heinhuis Breakdown of academic impact, for papers by Chimera R. Peet Breakdown of academic impact, for papers by Winifred Lo
Rankless by CCL
2026